Explore

Trendline Trendline
CareDx Reports 39% Revenue Growth in Q1 2026, Raises Annual Guidance

CareDx Reports 39% Revenue Growth in Q1 2026, Raises Annual Guidance

CareDx Reports 39% Revenue Growth in Q1 2026, Raises Annual Guidance
Trendline Trendline
Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026

Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026

Eli Lilly's Aggressive M Strategy Surpasses $21 Billion in 2026
Reuters Reuters
Kone to buy rival TK Elevator in $34.4 billion cash and stock deal

Kone to buy rival TK Elevator in $34.4 billion cash and stock deal

HELSINKI, April 29 (Reuters) - Finnish lift maker Kone said on Wednesday it had agreed to buy its German rival TK Elevator in a cash and stock transaction valued at 29.4 billion euros ($34.4 billion), which would create ​the world's largest lift maker.
Trendline Trendline
IKS Health to Acquire TruBridge in $557 Million Deal to Enhance Rural Healthcare

IKS Health to Acquire TruBridge in $557 Million Deal to Enhance Rural Healthcare

IKS Health to Acquire TruBridge in $557 Million Deal to Enhance Rural Healthcare
Trendline Trendline
Intellia Therapeutics Announces Positive Phase 3 Results for Gene Editing Treatment in Hereditary Angioedema

Intellia Therapeutics Announces Positive Phase 3 Results for Gene Editing Treatment in Hereditary Angioedema

Intellia Therapeutics Announces Positive Phase 3 Results for Gene Editing Treatment in Hereditary Angioedema
Reuters Reuters
Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline.
Trendline Trendline
Sun Pharma to Acquire U.S. Firm Organon in $11.75 Billion Deal

Sun Pharma to Acquire U.S. Firm Organon in $11.75 Billion Deal

Sun Pharma to Acquire U.S. Firm Organon in $11.75 Billion Deal
Rapid Read Rapid Read
Intellia Therapeutics' Crispr-Based Treatment Achieves Success in Pivotal Trial

Intellia Therapeutics' Crispr-Based Treatment Achieves Success in Pivotal Trial

Intellia Therapeutics has announced that its Crispr-based treatment for hereditary angioedema has met its goals in a late-stage trial. The treatment, which edits DNA in vivo to turn off a gene causing overproduction of a peptide, reduced swelling attacks by 87% compared to a placebo. This marks a significant milestone in gene editing, as it is the first Phase 3 data for in vivo Crispr treatment. The company plans to seek FDA approval and aims to launch the treatment in the U.S. next year.
Reuters Reuters
Critical Metals agrees to buy European Lithium for about $835 million

Critical Metals agrees to buy European Lithium for about $835 million

April 27 (Reuters) - U.S.-based miner Critical Metals has signed a letter of intent to purchase all outstanding shares of European Lithium in an about $835 million deal, a move that would secure its full ownership of Greenland's Tanbreez rare earth project.
Rapid Read Rapid Read
China Blocks Meta's Acquisition of AI Startup Manus Amid Tech Rivalry

China Blocks Meta's Acquisition of AI Startup Manus Amid Tech Rivalry

China has blocked Meta's acquisition of the AI startup Manus, citing concerns over the transfer of advanced technology. The decision was made by China's National Development and Reform Commission, which required all parties to withdraw from the deal. This move comes amid increasing scrutiny of the AI industry by Chinese authorities, reflecting the intensifying geopolitical rivalry with the U.S. over technology. Meta had announced the acquisition in December, aiming to expand its AI offerings, but China's intervention highlights the challenges U.S. tech companies face in acquiring firms with Chinese connections.
Rapid Read Rapid Read
Alterity Therapeutics Advances Toward Phase 3 Trial for MSA Treatment

Alterity Therapeutics Advances Toward Phase 3 Trial for MSA Treatment

Alterity Therapeutics has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its Phase 3 development program for ATH434, a treatment for Multiple System Atrophy (MSA). This feedback follows a Type C Meeting with the FDA, focusing on the chemistry, manufacturing, and control elements of the program. MSA is a rare neurodegenerative disease with no approved disease-modifying treatments. The FDA's endorsement of Alterity's manufacturing plans is a critical step toward initiating the Phase 3 trial. Alterity aims to finalize its plans with the FDA at an End-of-Phase 2 meeting scheduled for mid-2026.
Trendline Trendline
Intellia Therapeutics Begins FDA Submission for CRISPR-Based Hereditary Angioedema Treatment

Intellia Therapeutics Begins FDA Submission for CRISPR-Based Hereditary Angioedema Treatment

Intellia Therapeutics Begins FDA Submission for CRISPR-Based Hereditary Angioedema Treatment